Shopping Cart
- Remove All
Your shopping cart is currently empty
ELOVL6-IN-5 (compound B) acts as an inhibitor targeting the elongase enzyme of the long-chain fatty acid family 6 (ELOVL6). This enzyme is pivotal in the elongation process of saturated and monounsaturated long-chain fatty acids, marking it as a strategic target for diabetes intervention. In a mouse model of diet-induced obesity (DIO), ELOVL6-IN-5 effectively reduces hepatic fatty acid levels. However, it fails to enhance insulin sensitivity.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 25 mg | $1,520 | 6-8 weeks | |
| 50 mg | $1,980 | 6-8 weeks | |
| 100 mg | $2,500 | 6-8 weeks |
| Description | ELOVL6-IN-5 (compound B) acts as an inhibitor targeting the elongase enzyme of the long-chain fatty acid family 6 (ELOVL6). This enzyme is pivotal in the elongation process of saturated and monounsaturated long-chain fatty acids, marking it as a strategic target for diabetes intervention. In a mouse model of diet-induced obesity (DIO), ELOVL6-IN-5 effectively reduces hepatic fatty acid levels. However, it fails to enhance insulin sensitivity. |
| Molecular Weight | 439.45 |
| Formula | C20H20F3N3O3S |
| Cas No. | 1135000-36-0 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.